BCL3 and acute myeloid leukemia: In contrast to controls (median 0.0032, range 1.25E5–0.0072), BCL3 (median 0.0071, range 0.00032–5.5277) BCL3 mRNA levels were significantly decreased in AML patients (p < 0.001, Fig. 1a).